Skip to content

Abdominal Fat and Imaging Measurements of Heart Disease

Visceral Obesity/Ectopic Fat and Non-invasive Markers of Atherosclerosis: A Cardiometabolic-cardiovascular Imaging Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01447745
Enrollment
357
Registered
2011-10-06
Start date
2013-03-31
Completion date
2020-02-29
Last updated
2025-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Metabolic Syndrome, Visceral Obesity

Keywords

Magnetic resonance imaging (MRI), Computed tomography (CT), Visceral obesity, Cardiometabolic risk, Atherosclerosis, Ectopic fat, Carotid plaque

Brief summary

Although it is frequently mentioned in the media that overweight and obesity have reached epidemic proportions worldwide and in this country, some Canadians are perplexed and sometimes confused about the role of obesity in diabetes and heart disease. In fact, the investigators even hear from time to time that there could be healthy obese individuals. In clinical practice, assessment of obesity as a risk factor for cardiovascular disease (CVD) remains a challenge as even some physicians are confused. However, studies conducted in our laboratory and by other research teams around the world over the last 20 years have clearly shown that body shape is more important than body size when evaluating the risk of overweight/obesity and that high accumulation of abdominal fat (excess belly fat) increases the risk of diabetes and cardiovascular disease (CVD). The investigators now need to better understand the link between excess belly fat and atherosclerosis (the thickening of artery walls by fatty deposits, also referred to as atherosclerotic plaque), leading to complications such as angina (chest pain) and myocardial infarction (heart attacks). Using non-invasive imaging techniques such as magnetic resonance imaging, the investigators therefore propose to examine the relationships between measures of fatness and of abdominal fat and the size of atherosclerotic plaque in large blood vessels of apparently healthy human subjects. This study is also a unique opportunity to look, for the first time, at the relationship between belly fat, blood sugar, several well-known risk factors for heart disease (cholesterol, blood pressure, cardiorespiratory fitness, etc.) and the size of atherosclerotic plaques. This research program should pave the way to the development of new improved preventive/therapeutic approaches focusing not on body weight but rather on abdominal fat and associated blood abnormalities which are predictive of the development of atherosclerotic plaques leading to the premature development of heart disease.

Interventions

None listed

Sponsors

Canadian Institutes of Health Research (CIHR)
CollaboratorOTHER_GOV
Laval University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
35 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Men and women aged 35-65 years

Exclusion criteria

* Massive obesity (BMI ≥ 40 kg/m2) * Pharmacological treatment for lipids, hypertension and/or type 2 diabetes * Clinical signs of cardiovascular disease * Chronic inflammatory or auto-immune diseases * Pulmonary diseases on corticosteroids * Cancers not in remission * History or clinical evidence of coronary heart disease (CHD) * History of revascularisation procedures * Current smoking * Hormonal replacement therapy

Design outcomes

Primary

MeasureTime frameDescription
Change in carotid vessel wall volume measured by magnetic resonance imaging (MRI)Change between baseline and 3-year follow-upCross-sectional and longitudinal analyses of the relationships between indices of body fat distribution, visceral adiposity/ectopic fat deposition, cardiorespiratory fitness and non-invasive measurements of macrovascular atherosclerosis

Secondary

MeasureTime frameDescription
Change in abdominal adipose tissue measured by computed tomography (CT)Change between baseline and 3-year follow-upVisceral and subcutaneous adipose tissue will be determined at both L2-L3 and L4-L5 levels
Change in epi- and pericardial fat measured by magnetic resonance imaging (MRI)Change between baseline and 3-year follow-up

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026